Background: Human epididymis secretory protein 4 (HE4) is a secreted glycosylated protein belonging to the WFDC family, which is an ideal biomarker in ovarian cancer. However, the role of HE4 in lung cancer is still unclear. The study aimed to evaluate serum levels of HE4 as a prognostic biomarker in patients with non-small cell lung cancer (NSCLC). 
INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths worldwide, accounts for 20% of all cancer deaths in some developing countries such as China, and ranks highest for both incidence and mortality in the world [1] . According to the biological characteristics, lung cancer is divided into two main categories: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). About 80 -85% of lung cancer is non-small lung cancer, which includes squamous cell lung carcinoma and lung adenocarcinoma [2] . Lung adenocarcinoma is the major histological type (52.5%) [3] . Epidemiological surveys report more than 75% of patients are diagnosed with lung cancer at an advanced stage. Lung cancer remains an aggressive malignant tumor with a 5-year survival rate of only 15% [4] . Therefore, it is critical to detect lung cancer at an early stage using sensitive diagnostic and prognostic biomarkers. To date there are a number of serum biomarkers that have been found to be elevated in the serum of patients with lung cancer; however, the biomarkers lack sufficient sensitivity or specificity to obtain a reliable diagnosis of or prognosis for lung cancer [5, 6] . Consequently, to provide better noninvasive diagnosis and treatment strategies, there is an urgent need to identify useful biomarkers for lung cancer. Human epididymis protein 4 (HE4) was first identified in the epithelium of the distal epididymis, which has been described as a novel serum marker for the early diagnosis and recurrence monitoring of malignant tumors, such as ovarian cancer, endometrial carcinoma, and breast cancer [7] [8] [9] [10] . However, the role of HE4 in NSCLC remains unknown. Several studies have found significantly increased HE4 levels in tumor tissues and serum of lung cancer [11] . In addition, HE4 is closely associated with occurrence, development, and prognosis of lung cancer [12, 13] . In the present study, we further analyzed the value of serum HE4 levels in the diagnosis and prognosis of NSCLC.
MATERIALS AND METHODS

Serum samples and patients
Serum samples were collected from lung cancer patients who visited the Thoracic Surgery Department of The Jiangsu Cancer Hospital between January 2013 and January 2015. Patients with a recent history of any cancer other than lung cancer were excluded. In addition, the patients had not received any therapeutic procedures before collection of serum samples. A total of 217 patients with NSCLC (116: adenocarcinoma; 81: squamous cell carcinoma; 20: large cell carcinoma) were involved in this study. Lung cancers were staged (41 Is, 46 IIs, 27 IIIas, 43 IIIbs, and 60 IVs) according to the Tumor Node Metastasis (TNM) classification system developed by the American Joint Committee on Cancer (AJCC) [14] . Age-matched control serum was obtained from 110 healthy volunteers. Furthermore, 80 patients with benign pulmonary diseases including hamartoma, inflammatory pseudotumor, and pneumonia were collected.
Laboratory methods
All blood samples were obtained from study subjects of the three groups in the morning after 12 hours of fasting. For patients in the case and benign control groups, collection time was before the patients received relevant treatment. Serum samples were extracted from whole blood after centrifugation (3,000 rpm, 10 minutes) and stored at -80°C until further processing. The concentration of HE4 was measured with electrochemiluminescence assays in a Roche E601 Immunoassay Analyzer according to manufacturer's protocols.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics Version 20 (IBM Corp.; Armonk, NY, USA) and GraphPad Prism v5.0 (Graphpad Software Inc.). To analyze the distribution of tumor markers in subsets of patients, results were compared using Mann-Whitney U test and Kruskal-Wallis test, and the data are reported as median (range). The efficacy of the tumor markers was evaluated by sensitivity, specificity, and area under receiver operating characteristic (ROC) curve (AUC). The sensitivity-specificity relationship was determined using Youden's index J. Spearman's correlation test was used to examine the correlation between HE4 levels and other tumor markers. In addition, survival curves were constructed with the Kaplan-Meier method and compared using log-rank test. Cox proportional hazards regression analysis was used to estimate the hazard ratios of independent factors for survival. Two-sided p-value of less than 0.05 was considered statistically significant.
RESULTS
Evaluation of serum HE4 levels in patients with lung cancer
The general characteristics of study subjects are displayed in Table 1 Figure A) . The difference between benign and healthy control groups was not statistically significant (p = 0.057). When all lung cancer serum samples were segregated based upon pathological tumor/node/metastasis (pTNM) stage, the gradual increase in serum HE4 levels was clearly discernible. Serum concentrations of HE4 were significantly higher in all clinical stages of the disease, as compared to healthy controls (p < 0.05; Figure 1A ). Next, we compared the levels of HE4 in the NSCLC histological subgroups. A trend toward higher serum levels of HE4 was found in adenocarcinoma patients compared to patients with squamous carcinoma (120. 
Diagnostic value of serum HE4 for patients with lung cancer
In order to evaluate the discriminative power of HE4 between controls and NSCLC, the area under the ROC curve (AUC) was performed. As shown in Figure 2A , ROC-AUC of HE4 for differentiating all NSCLC patients from healthy controls was 0.898 (95% confidence interval (CI) [0.862 -0.935]) and was statistically different from the non-discriminant bisector (z test; p < 0.001). The Youden's index J was 0.68 and was associated with a cutoff value of 78.84 pmol/L for HE4, corresponding to a sensitivity of 84.2% and a specificity of 78.3%. CEA and Cyfra21-1 are two widely used tumor markers for lung cancer. We also examined their serum levels; HE4 was significantly correlated with CEA (Spearman's r = 0.325; p = 0.027), Cyfra21-1 (Spearman's r = 0.413; p = 0.033). The sensitivities of CEA and Cyfra21-1 were respectively 61.7% and 69.2%, which were lower than those of HE4 (Supplementary Figure 1) . To differentiate NSCLC patients from benign lung disease patients, a cutoff value of 81.26 pmol/L yielded a sensitivity of 82.8% and a specificity of 72.7% ( Figure 2B ). Furthermore, in the NSCLC subgroups, the ROC-AUC of 0.909 was specified for adenocarcinoma from healthy controls with 78.8% sensitivity and 90.3% specificity at a cutoff value of 72.70 pmol/L ( Figure 2C ). While a ROC-AUC of 0.689 (95% CI, 0.601 -0.779) differentiated squamous carcinoma from healthy controls, with a sensitivity of 63.1% and a specificity of 72.1% ( Figure 2D ). The results demonstrated that HE4 level was a better diagnostic marker for lung adenocarcinoma than squamous cell lung carcinoma. 
Correlation of serum HE4 levels with clinicopathological factors
In the validation set, 72.81% (158/217) of lung cancer patients showed higher levels of HE4 based on the cutoff point (78.84 pmol/L). The correlation of serum HE4 levels with clinicopathological factors of lung cancer patients was statistically analyzed in Table 2 . High level of serum HE4 was significantly correlated with histological type (p = 0.001), high TNM stage (p < 0.001), and lymph node metastasis (p < 0.001), suggesting that higher HE4 levels are associated with tumor progression in lung cancer. However, serum HE4 levels were not associated with age, gender, and smoking status (p = 0.933, 0.878 and 0.531, respectively).
Serum HE4 levels are associated with lung cancer progression and poor prognosis Next, the association between serum HE4 levels and overall survival of NSCLC patients was evaluated.
Complete follow-up data were available for 203 cases, which were categorized as low serum HE4 level and high serum HE4 level (based on the cutoff value of 78.84 pmol/L). Their clinicopathological characteristics were shown in Supplementary Table 1. Assessment of survival in patients with NSCLC revealed that higher level of HE4 was correlated with adverse survival of patients. At the time of the analysis, with a minimum follow-up of two years and four months, 135 patients (66.5%) had died during the follow-up period. The median observation time for overall survival was 21 months (range, 4 -49 months; Figure 3A ). As showed in Figure 3B , the higher serum HE4 group had a statistically significantly worse prognosis than the lower serum HE4 group (log-rank test: p = 0.007). In addition, the potential prognostic value of HE4 levels in different subgroups of NSCLC patients was detected according to the histology type. There was a statistically significant difference in the overall survival between the high- er and lower HE4 level in the adenocarcinoma. We found that the median survival was only 18 months (95% CI, 16.1 -22.8) for patients with higher serum HE4 level, whereas the median survival time of those with lower serum HE4 level was 30 months (95% CI, 24.9 -33.7) in Figure 3C (log-rank test: p = 0.001).
When we examined the effect of HE4 on overall survival in squamous carcinoma, no significant difference was found (p = 0.132; data not shown). Univariate Cox regression analysis revealed that histological type, TNM stage, lymph node metastasis, and serum HE4 levels were significantly correlated with overall survival (p = 0.032, 0.029, 0.011, and 0.036, respectively). Results of the multivariate analysis indicated that TNM stage and lymph node metastasis status [hazard ratio (HR) = 1.781; 95% CI, 1.134 -5.832; p = 0.031 and HR = 2.254; 95% CI, 1.194 -8.779; p = 0.027, respectively], and serum HE4 levels (HR = 2.031; 95% CI, 1.157 -7.399; p = 0.023) were the independent prognostic factors for overall survival (Table 3) .
DISCUSSION
In our previous study, we showed that high HE4 levels in the serum are related to poor NSCLC prognosis as patients with high serum level of HE4 before treatment had shorter survival, especially in patients with adenocarcinoma. HE4 was widely used in the routine diagnostics and tumor progression of ovarian cancer [15] . Being a proteinase inhibitor, it is a component of the innate immune responses in the lung and respiratory tract [12] . Several studies suggested that serum HE4 could be a marker of NSCLC [11, 12, 16] . We evaluated serum HE4 levels in the patients with NSCLC or benign lung disease and healthy controls. Obviously, serum levels of HE4 were significantly higher in the case group than benign or healthy counterparts. When all lung cancer serum samples were segregated based upon pathological tumor/node/metastasis (pTNM) stage, the gradual increase in serum HE4 levels was clearly discernible. In the other words, serum HE4 levels had a tendency to rise with increasing pTNM stage and HE4 levels associated with pTNM stage. In the lung cancer histological subgroups, a trend toward higher serum levels of HE4 was found in adenocarcinoma patients compared to patients with squamous carcinoma. The association between serum HE4 levels and overall survival of NSCLC patients was evaluated. KaplanMeier survival cure analysis revealed that higher levels of HE4 in their pre-treatment serum had a significantly adverse overall survival. The median observation time for overall survival was 21 months (range, 4 -49 months). The higher serum HE4 (> 78.84 pmol/L) group had a statistically significantly worse prognosis than lower serum HE4 group (≤ 78.84 pmol/L) (logrank test: p = 0.007). In addition, the potential prognostic value of HE4 levels in different subgroups of NSCLC patients was detected according to the histology type. There was a statistically significant difference in the overall survival between the higher HE4 levels and lower HE4 levels in the adenocarcinoma (18 months vs. 30 months; log-rank test: p = 0.001). However, we did not find a significant difference in squamous carcinoma. Cox proportional hazard regression model analysis revealed that high serum HE4 levels were associated with an increased risk of death from NSCLC. Moreover, high levels of HE4 were an independent risk factor indicating poor prognosis for patients with NSCLC. This was in agreement with research reported by Huang et al. [20] . In addition, the co-hort of patients in the current study (n = 217) was larger than in the previous studies (146 cases in Huang et al.)
CONCLUSION
Higher serum levels of HE4 predict poor prognosis in NSCLC patients, especially in patients with adenocarcinoma.
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